NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
Key Details
- 1NCCN updated guidelines to recommend AI-based 5-year breast cancer risk assessment using routine mammograms.
- 2Patients with an AI-predicted 5-year risk ≥1.7% should be considered for supplemental imaging (MRI or ultrasound).
- 3Risk evaluations should begin at age 35, earlier than the previous standard of 40.
- 4Re-assessment over time is advised due to changes in breast tissue.
- 5The Clairity Breast platform, FDA-cleared for this purpose, is highlighted and is reportedly over 3x more accurate at risk prediction than density reporting by radiologists.
Why It Matters
These recommendations will likely accelerate adoption of AI tools in breast imaging, standardizing risk stratification and personalized screening. Radiologists and imaging providers must prepare for new workflows and patient stratification protocols based on AI outputs.
Source
Radiology Business
Related News
•Radiology Business
UCLA Review Evaluates Breast AI for Early Cancer Detection
A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.
•Radiology Business
Vara's AI Gains World's First Approval for Radiologist-Free Mammogram Triage
Vara has secured the world's first regulatory approval for an AI tool that autonomously classifies certain mammograms as normal, bypassing radiologist review.
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.